tanezumab

Home
Ligands
tanezumab

GtoPdb Ligand ID: 8415

Synonyms: PF-04383119 | PF04383119 | RN624

Comment: Tanezumab is an investigational monoclonal antibody targeting nerve growth factor (NGF). NGF is a neurotrophin that regulates the development and survival of a select population of neurons through the binding and activation of the neurotrophic receptor tyrosine kinase 1 (TrkA receptor). Elevated levels of NGF have been associated with painful pathologies including diabetic neuropathy, fibromyalgia and osteoarthritis. Inhibition of NGF signalling has been explored for anti-pain potential.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. BLAST peptide sequence analysis reveals identical sequences are claimed in patent US7449616.

References
1. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg KM, Dyck PJ. (2015) Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med, 16 (6): 1163-76. [PMID:25594611]
2. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. (2013) Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum, 65 (7): 1795-803. [PMID:23553790]
3. Gimbel JS, Kivitz AJ, Bramson C, Nemeth MA, Keller DS, Brown MT, West CR, Verburg KM. (2014) Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain, 155 (9): 1793-801. [PMID:24937440]
4. Hochberg MC. (2015) Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthr Cartil, 23 Suppl 1: S18-21. [PMID:25527216]
5. Hu R, Song Y-F, Yang Z-Y, Zhang C, Tan B. (2021) Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis. Frontiers in Pharmacology, [Epub ahead of print]. DOI: https://doi.org/10.3389/fphar.2021.614753
6. Markman JD, Bolash RB, McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer FW, Li DJ, Viktrup L, Bramson C et al.. (2020) Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain, 161 (9): 2068-2078. [PMID:32453139]
7. Pons J, Rosenthal A. (2008) Anti-NGF antibodies and methods using same. Patent number: US7449616 B2. Assignee: Pfizer Inc.. Priority date: 24/12/2002. Publication date: 11/11/2008.
8. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. (2019) Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial. JAMA, 322 (1): 37-48. [PMID:31265100]
9. Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR. (2020) Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study. Semin Arthritis Rheum, 50 (3): 387-393. [PMID:32252976]
10. Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, West CR, Wolfram G, Brown MT. (2015) Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain, 156 (9): 1703-13. [PMID:25919474]

References

1. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, West CR, Verburg KM, Dyck PJ. (2015)
Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain.
Pain Med, 16 (6): 1163-76. [PMID:25594611]

2. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. (2013)
Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Arthritis Rheum, 65 (7): 1795-803. [PMID:23553790]

3. Gimbel JS, Kivitz AJ, Bramson C, Nemeth MA, Keller DS, Brown MT, West CR, Verburg KM. (2014)
Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain.
Pain, 155 (9): 1793-801. [PMID:24937440]

4. Hochberg MC. (2015)
Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.
Osteoarthr Cartil, 23 Suppl 1: S18-21. [PMID:25527216]

5. Hu R, Song Y-F, Yang Z-Y, Zhang C, Tan B. (2021)
Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis.
Frontiers in Pharmacology, [Epub ahead of print]. DOI: https://doi.org/10.3389/fphar.2021.614753

6. Markman JD, Bolash RB, McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer FW, Li DJ, Viktrup L, Bramson C et al.. (2020)
Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
Pain, 161 (9): 2068-2078. [PMID:32453139]

7. Pons J, Rosenthal A. (2008)
Anti-NGF antibodies and methods using same.
Patent number: US7449616 B2. Assignee: Pfizer Inc.. Priority date: 24/12/2002. Publication date: 11/11/2008.

8. Schnitzer TJ, Easton R, Pang S, Levinson DJ, Pixton G, Viktrup L, Davignon I, Brown MT, West CR, Verburg KM. (2019)
Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
JAMA, 322 (1): 37-48. [PMID:31265100]

9. Schnitzer TJ, Khan A, Bessette L, Davignon I, Brown MT, Pixton G, Prucka WR, Tive L, Viktrup L, West CR. (2020)
Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
Semin Arthritis Rheum, 50 (3): 387-393. [PMID:32252976]

10. Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, West CR, Wolfram G, Brown MT. (2015)
Efficacy and safety of tanezumab in the treatment of pain from bone metastases.
Pain, 156 (9): 1703-13. [PMID:25919474]